OMEICOS Therapeutics GmbH - Collaborations

Academic collaborations

ico linkMax Delbrück Center in the Helmhotz Association (MDC Berlin, Germany)

OMEICOS Therapeutics is a spin-off from the MDC Berlin. Since its inception, OMEICOS has continued a close collaboration with the working groups of OMEICOS’ co-founders
Dr. Wolf-Hagen Schunck and Dr. Dominik Müller to fully elucidate the molecular mode of action of natural Cytochrome P450-dependent metabolites of omega-3 fatty acids and their synthetic analogs activating a novel protective pathway in cardiomyocytes and other cell types.  


ico linkMontreal Heart Institute (MHI, Montreal, Canada)

OMEICOS Therapeutics is working closely together with the research group of Dr. Stanley Nattel to investigate the anti-arrhythmic effect of OMEICOS’ compounds in atrial fibrillation.
Dr. Stanley Nattel’s lab is one of the world’s leading research teams focused on clinically-relevant mechanisms of atrial fibrillation, cardiac remodeling, ion channel molecular physiology and mechanisms of drug action.